Gene test may guide chemo choice for tough pancreatic cancer
NCT ID NCT05475366
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study aims to see if using five gene signatures from a patient's tumor can help doctors choose the best first chemotherapy for advanced pancreatic cancer. About 85 people with metastatic pancreatic cancer will have their tumor genes analyzed to pick between two standard chemo regimens. The main goal is to see if this personalized approach increases the number of patients whose tumors shrink significantly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
chemotherapy (FOLFIRINOX or Gem-nabP) chosen based on tumor gene signatures
What this could lead to
If successful, this could lead to a more personalized way to select chemotherapy for advanced pancreatic cancer, potentially improving how many patients respond to treatment.
What could go wrong
This is a small pilot study with only 85 participants, so results may not apply to everyone. The approach is experimental and may not improve outcomes or could be too complex for routine use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, PANCREATIC DUCTAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
CHU Robert Debré
RECRUITINGReims, 51092, France
Contact
-
Hôpital Beaujon
RECRUITINGClichy, 92210, France
Contact
-
Hôpital Claude Hurriez
RECRUITINGLille, 59037, France
Contact
-
Hôpital HENRI MONDOR
RECRUITINGCréteil, 94010, France
Contact
-
Hôpital PAUL BROUSSE 12 Avenue Paul Vaillant Couturier
RECRUITINGVillejuif, 94800, France
Contact
-
Institut Curie
RECRUITINGSaint-Cloud, 92210, France
Contact
-
Institut Paoli-Calmettes
RECRUITINGMarseille, 13573, France
Contact